CDEK
← All organizations

Ascendis Pharma, Inc.

For profitContributed to NMEWebsite ↗

Also known as: Ascendis Pharma | Ascendis Pharma A/S | Ascendis Pharma A/S European Medical Monitor/Medical Expert | Ascendis Pharma A/S North American Medical Monitor/Medical Expert | ASCENDIS PHARMA BONE | Ascendis Pharma Bone Diseases A/S | ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S | Ascendis Pharma Endocrinology Division A/S | Ascendis Pharma Growth Disorders A/S | Ascendis Pharma Inc. | Ascendis Pharma, Inc. | Ascendis Pharma Oncology Division A/S

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Nov 1, 2009

First marketed drug

Aug 25, 2021

First NDA

Aug 25, 2021

Last known activity

Nov 30, 2025

Timeline

2000s

  1. Jun 1, 2006

    Ascendis Pharma, Inc.— Founded

  2. Dec 13, 2007

    Complex Biosystems— Acquired

2020s

  1. Aug 25, 2021

    lonapegsomatropin— Marketing Organization

  2. Aug 25, 2021

    lonapegsomatropin— NDA Secondary Org

  3. Aug 9, 2024

    palopegteriparatide— NDA Organization

Drugs by trial phase (14 distinct, 26 trials)

Phase 1 (1 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (2)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (44)

Details

Founded
Palo Alto, CA, US Jun 1, 2006
First NDA
Aug 25, 2021
Last known activity
Nov 30, 2025

Designations held

  • Orphan drug
  • Priority review